Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
102.179,26
-0,23%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lantern Pharma Inc (LTRN) Lantern Pharma Inc (LTRN) Notizie

Lantern Pharma Inc

LTRN
4,95
0,14 (2,91%)
01 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
27/1/202513:55BWLantern Pharma Unveils Innovative AI-Powered Module to..
10/1/202522:05EDGAR2Form 8-K - Current report
09/12/202414:15BWLantern Pharma Announces First Patient Enrolled in Taiwan..
03/12/202414:00BWLantern Pharma's Investigational Drug-Candidate, LP-184,..
26/11/202414:45BWLantern Pharma & Starlight Therapeutics Present LP-184..
19/11/202414:00BWLantern Pharma Announces First Patient Dosed in Japan for..
07/11/202422:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202422:05EDGAR2Form 8-K - Current report
07/11/202422:05BWLantern Pharma Reports Third Quarter 2024 Financial Results..
05/11/202414:00BWStarlight Therapeutics Announces Inaugural Members of..
31/10/202413:00BWLantern Pharma to Report Third Quarter 2024 Operating &..
23/10/202414:45BWLantern Pharma to Present at the ThinkEquity Conference in..
21/10/202414:00BWLantern Pharma to Host & Participate in Two Public Webinars..
15/10/202415:07BWLantern Pharma’s Investigational Drug-Candidate, LP-184,..
23/9/202414:00BWLantern Pharma Announces Three U.S. FDA Rare Pediatric..
08/8/202422:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:01BWLantern Pharma Reports Second Quarter 2024 Financial Results..
07/8/202415:31BW Lantern Pharma Highlights Promising Preclinical Results of..
05/8/202414:00BWLantern Pharma Announces Positive Clinical Update from..
01/8/202414:00BWLantern Pharma to Report Second Quarter 2024 Operating &..
17/7/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202414:30BWLantern Pharma Achieves Key Milestone Towards Development of..
17/6/202422:15EDGAR2Form 8-K - Current report
12/6/202413:30BWLantern Pharma Receives Certificate of Patent from Japanese..
11/6/202406:16EDGAR2Form EFFECT - Notice of Effectiveness
24/5/202422:09EDGAR2Form 8-K - Current report
24/5/202422:08EDGAR2Form S-8 - Securities to be offered to employees in employee..
24/5/202422:06EDGAR2Form S-3 - Registration statement under Securities Act of..
13/5/202407:30BWOregon Therapeutics et Lantern Pharma lancent une..
09/5/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:02BWLantern Pharma Reports First Quarter 2024 Financial Results..
06/5/202409:00BWOregon Therapeutics & Lantern Pharma Launch Strategic AI..
02/5/202413:30BWLantern Pharma to Report First Quarter 2024 Operating &..
24/4/202414:00BWLantern Pharma Launches “Webinar Wednesdays” Featuring..
22/4/202414:12BWLantern Pharma Receives Regulatory Approval to Expand..
18/3/202421:02BWLantern Pharma Reports Fourth Quarter & Fiscal Year 2023..
18/3/202412:12IHMARKETNEWSAnticipation Builds on Wall Street for Federal Reserve’s..
15/3/202413:00BWLantern Pharma Announces Initial Patients Dosed in..
11/3/202412:30BWLantern Pharma to Report Fourth Quarter and Fiscal Year 2023..
05/3/202414:01BWLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st..
04/3/202414:01BWLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion..
01/3/202403:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202414:01BWLantern Pharma Advances Unique ADC (Antibody Drug Conjugate)..
Apertura: 4,6801 Min: 4,6801 Max: 5,30
Chiusura: 4,81

La tua Cronologia

NASDAQ
LTRN
Lantern Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci